What is Protera?
Protera operates at the vanguard of the food industry, utilizing its proprietary madi platform to redefine how functional ingredients are developed. By integrating generative AI with sophisticated protein engineering, the company addresses critical bottlenecks in protein discovery and performance enhancement. This technological framework enables the creation of novel, high-performance proteins through precision fermentation, effectively bridging the gap between laboratory-scale innovation and industrial-grade manufacturing. Protera's market position is defined by its ability to provide scalable, sustainable solutions that cater to both advanced food product development and the creation of next-generation materials, positioning it as a key player in the global transition toward bio-based manufacturing.
How much funding has Protera raised?
Protera has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2021): $10M with participation from SOSV LLC, ICL Planet, Sofinnova Partners, and Bimbo Group
Key Investors in Protera
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations.
SOSV LLC
A global venture capital firm focused on deep tech and life sciences, known for its extensive accelerator programs and early-stage support for hardware and biotech startups.
ICL Planet
The corporate venture arm of ICL Group, focusing on strategic investments in food tech, agriculture, and sustainable materials to drive innovation across the global food supply chain.
What's next for Protera?
With this major enterprise-level funding, Protera is well-positioned to accelerate its operational roadmap and scale its precision fermentation capabilities. The strategic focus will likely shift toward expanding the madi platform's utility, deepening its library of functional proteins, and strengthening commercial partnerships to integrate these ingredients into mainstream supply chains. As the company moves beyond its initial development phase, the emphasis will remain on optimizing production efficiency and securing regulatory milestones necessary for broad market adoption. Investors are closely monitoring Protera's ability to maintain its competitive edge in computational biology while navigating the complexities of scaling bio-industrial processes to meet global demand for sustainable, high-performance protein alternatives.
See full Protera company page
